Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Kwon, Mi  [Clear All Filters]
2014
Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega I, Serrano D, Anguita J, Buño I, Fores R, Regidor C, Marco JAGarcía, et al. Haplo-Cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant. 2014.
2018
Salgado M, Kwon M, Gálvez C, Badiola J, Nijhuis M, Bandera A, Balsalobre P, Miralles P, Buño I, Martinez-Laperche C, et al. Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Ann Intern Med. 2018.
2019
Bailén R, Pérez-Corral AMaría, Pascual C, Kwon M, Serrano D, Gayoso J, Balsalobre P, Muñoz C, Díez-Martín JLuis, Anguita J. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center. J Clin Apher. 2019.
Kwon M, Bailén R, Pascual-Cascón MJesús, Gallardo-Morillo AIsabel, Sola AGarcía, Balsalobre P, Solán L, Dorado N, Muñoz C, Serrano D, et al. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. Blood Adv. 2019;3(21):3351-3359.
Oarbeascoa G, Dorado N, Bailén R, Serrano D, Balsalobre P, Pradillo V, Guinea J, Padilla B, Sancho M, Machado M, et al. Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. Chemotherapy. 2019:1-5.
2020
Kwon M, Bailén R, Díez-Martín JLuis. Evolution of the role of haploidentical stem cell transplantation: past, present, and future. Expert Rev Hematol. 2020:1-16.
2021
González MJ, Urizar E, Urtaran-Laresgoiti M, Nuño-Solinís R, Lázaro-Pérez E, Vázquez L, Pascual-Cascón MJesús, Solano C, Kwon M, Gallego C, et al. Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs. PLoS One. 2021;16(8):e0254135.
2022
Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CPinho, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJurado, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022;9(1):e14-e25.
Bailén R, Pascual-Cascón MJesús, Guerreiro M, López-Corral L, Chinea A, Bermúdez A, Sampol A, Heras I, García-Torres E, Torres M, et al. Post-transplant cyclophosphamide after HLA identical compared to Haploidentical donor transplant in Acute Myeloid Leukemia: a study on behalf of GETH-TC. Transplant Cell Ther. 2022.
Vallejo M, Muñiz P, Kwon M, Solán L, Bailén R, Carbonell D, Chicano M, Suárez-González J, Catalán P, Bellón JMaría, et al. Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms. Ann Hematol. 2022.
2023
Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang X-J, Hermine O, Philippe L, Couronné L, et al. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. Leukemia. 2023.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):106.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):58.
Gómez-Centurión I, Rojas RMaria Mart, Bailén R, Muñoz C, Sabell S, Oarbeascoa G, Fernández-Caldas P, Carbonell D, Gayoso J, Martinez-Laperche C, et al. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide. Ann Hematol. 2023.
Coll CFerra, de la Fe MMorgades, García LPrieto, Vaz CPinho, Fernando MInmaculada, Almorox RBailen, Cadenas IGarcía, Muñoz MCalabuig, Ripa TZudaire, Al-Sibai JZanabili, et al. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. Eur J Haematol. 2023.
Solano C, Castro-Rebollo P, Pérez-Martínez A, López-Corral L, Barba-Suñol P, Kwon M, Ortiz V, Sanz-Caballer J, Caballero ACarolina, Martínez J, et al. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study. BMJ Open. 2023;13(7):e071371.
Velázquez GFilippini, Labopin M, Tischer J, Raiola AMaria, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois C-E, Kröger N, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.